-

Phreesia’s Danielle Lynch Named One of MM+M’s ‘Women to Watch’ for 2022

RALEIGH, N.C.--(BUSINESS WIRE)--Phreesia is pleased to announce that the healthcare marketing industry trade MM+M has named Danielle Lynch, Vice President, Client Experience, to its Women to Watch class of 2022.

Now in its seventh year, the program recognizes successful leaders and up-and-coming talent in the industry who have inspired their colleagues, showcased new ways of doing business and taken healthcare marketing to new heights. Lynch was chosen as one of just 25 women to receive this year’s honors.

“I’m honored to be recognized by MM+M alongside such esteemed women leaders in the healthcare marketing field,” Lynch said. “I’m incredibly proud of the Phreesia Life Sciences team and the success we’ve achieved through hard work and collaboration.”

Since playing a pivotal role in taking Phreesia public in 2019, Lynch has doubled the size of her team and helped increase Life Sciences revenue by nearly 100%. She is admired by her colleagues for her innovation, tenacity, and her continued contributions to Phreesia's mission of creating a better, more engaging healthcare experience.

“We are thrilled to see Danielle awarded this well-deserved honor,” David Linetsky, Phreesia’s Senior Vice President, Life Sciences, said. “Danielle built the Client Experience team—the engine behind Phreesia Life Sciences’ significant growth—from the ground up, and her vision and leadership have been instrumental to the team’s success.”

About Phreesia Life Sciences

Phreesia empowers life sciences companies to connect meaningfully with clinically relevant patients, delivering targeted health content in a one-to-one setting. Our PatientConnect offering identifies and motivates the right patients to initiate meaningful brand conversations, and our PatientInsights product enables our clients to better understand their target patient populations.

Phreesia meets patients where they are, both virtually and in-person, and reaches them at multiple touchpoints throughout their healthcare journey. To learn more about Phreesia Life Sciences, visit lifesciences.phreesia.com.

Contacts

Media Contact:
Carly Helfand
chelfand@phreesia.com
332-910-6768

Phreesia

NYSE:PHR

Release Versions

Contacts

Media Contact:
Carly Helfand
chelfand@phreesia.com
332-910-6768

More News From Phreesia

Phreesia Announces Refinancing of Bridge Loan with New $275 Million Revolving Credit Facility

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) ("Phreesia" or the "Company") today announced the refinancing of its existing bridge loan (the “Bridge Loan”) by its entry into a new credit agreement providing for a senior secured revolving credit facility (the "New Credit Facility") of up to $275 million in aggregate principal amount, with Capital One, National Association (“Capital One”) serving as agent for the lenders. The Company borrowed approximately $92.2...

Phreesia’s Tiffany McGee Named a Top Woman Leader in Software

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia announces that Tiffany McGee, Assistant General Counsel, Commercial Contracts, has been named to Top Women Leaders in Software....

Phreesia Named to the 2026 Capterra Shortlist for Appointment Scheduling

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to the 2026 Capterra Shortlist for Appointment Scheduling. The Capterra Shortlist is an independent assessment that uses a proprietary blend of user ratings and popularity signals to identify leading products across software categories. Phreesia was named to four Capterra Shortlists in 2025, including for Patient Engagement. “Recognition from Capterra is especially...
Back to Newsroom